Get started
Work

Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design

Year: 2010
Type: article
Abstract: Pulmonary involvement including interstitial lung disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (scleroderma; SSc). This article reviews the current evidence based medicine regarding available therapies for SSc-ILD ; discusses the lessons learned from recent SSc-ILD randomized controlled trials (RCTs); and proposes outcome measures and recommendations for design of future RCTs for SSc-ILD.
DOI: 10.2174/157339710791330768
Authors: Dinesh Khanna, James R. Seibold, Athol Wells, Oliver Distler, Yannick Allanore, Chris Denton, Daniel E. Furst
Institutions: University of California, Los Angeles, UConn Health, Royal Brompton Hospital, University Hospital Zurich, Hôpital Cochin, Université Paris Descartes, The Royal Free Hospital
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2156611047
FWCI: 0.576
Cites: 62
Cited by: 29
Related to: 10